Dr. Mirza on the ENGOT-OV42-NSGO/AVANOVA-Triplet Trial in Recurrent Ovarian Cancer

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the planned phase III ENGOT-OV42-NSGO/AVANOVA trial in platinum-sensitive, recurrent ovarian cancer.

In the phase III ENGOT-OV42-NSGO/AVANOVA trial, patients with platinum-sensitive, recurrent ovarian cancer will be randomized to 1 of 3 arms: the combination of niraparib (Zejula) and bevacizumab (Avastin), niraparib/bevacizumab plus the PD-1 inhibitor TSR-042, or standard of care chemotherapy, says Mirza. Prior data from the phase II NSGO-AVANOVA2/ENGOT-OV24 trial showed a significant improvement in progression-free survival with the combination of niraparib/bevacizumab versus niraparib alone in patients with platinum-sensitive, recurrent ovarian cancer.

Preclinical and early clinical data suggest that the addition of an immune checkpoint inhibitor to an antiangiogenic agent or PARP inhibitor could provide synergistic benefit, concludes Mirza.